Examples of using Stivarga in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Stivarga is not recommended for use in patients with severe hepatic impairment(Child-Pugh C) as Stivarga has not been studied in this population.
If you have any questions about how Stivarga works or why this medicine has been prescribed for you,
Regorafenib was also approved under the name Stivarga® in the U.S. for the treatment of mCRC in September 2012 and for the treatment in gastrointestinal stromal tumors(GIST) in February 2013.
You must not breast-feed your baby during Stivarga treatment, as this medicine may interfere with the growth and development of your baby.
Regorafenib is approved under the brand name Stivarga® in more than 60 countries worldwide, including the U.S., Europe and Japan for the treatment of metastatic colorectal cancer.
Stivarga™ is the first medicine to show a significant improvement in overall survival in second-line treatment of patients with HCC for whom there was previously no further treatment option.
Teva will obtain a license to sell its generic version of Stivarga™ in the United States at a date shortly before the expiration of the patent protection for the active ingredient.
Eylea™, Stivarga™, Xofigo™ and Adempas™.
The EMA filing follows the EU approval of regorafenib(Stivarga®) for use in metastatic colorectal cancer in August 2013.
Eylea™, Stivarga™, Xofigo™ and Adempas™- again contributed to this pleasing performance with combined sales of €4.2 billion, compared with €2.9 billion in 2014.
Regorafenib is approved under the brand name Stivarga® in 90 countries for the treatment of mCRC
Stivarga is not recommended for use in patients with severe hepatic impairment(Child-Pugh C)
re-start Stivarga treatment, reduce dose by 40 mg(one tablet),
Also in December 2017, Bayer obtained marketing approval in China for Stivarga™(active ingredient:
BSC patients continued Stivarga treatment after disease progression.
in Japan for the marketing of Stivarga®(regorafenib) for the treatment of patients with gastrointestinal stromal tumor(GIST)
Berlin, June 27, 2014- The oncology compound regorafenib(Stivarga®) from Bayer has been recommended for approval by the European Committee for Medicinal Products for Human Use(CHMP)
Berlin, July 30, 2014- The oncology compound Stivarga®(regorafenib) from Bayer has been approved by the European Commission(EC) for the treatment
Other medicines and Stivarga.
How does Stivarga work?